A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 6, 2011, Pages

  McIntyre, Roger S ^a   McElroy, Susan L ^a   Eudicone, James M ^a   Forbes, Robert A ^a   Carlson, Berit X ^a   Baker, Ross A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; LITHIUM; PLACEBO;

ADULT; ARTICLE; BIPOLAR I DISORDER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UNDERWEIGHT; WEIGHT GAIN; WEIGHT REDUCTION; YOUNG MANIA RATING SCALE;

EID: 84856030050     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11m01182     Document Type: Article

References (43)

1. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. PubMed doi:10.1001/archpsyc.58.9.844
2. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69(4):514-519. PubMed doi:10.4088/JCP.v69n0401
3. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126(3):366-387. PubMed doi:10.1016/j.jad.2010.04.012
4. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10(2):342-348. PubMed doi:10.1111/j.1399-5618.2007.00520.x
5. Wolkowitz OM, Rothschild AJ. Psychoneuroendocrinology: The Scientific Basis of Clinical Practice. Washington, DC: American Psychiatric Publishing; 2003.
6. Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007;40(2):22-37, quiz 38-40. PubMed
7. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64(12):1426-1435. PubMed doi:10.4088/JCP.v64n1205
8. Allison DB, Newcomer JW, Dunn AL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36(4):341-350. PubMed doi:10.1016/j.amepre.2008.11.020
9. Newcomer JW. Second-Generation (atypical) Antipsychotics and Metabolic Effects: a Comprehensive Literature Review. CNS Drugs. 2005;19(suppl 1):1-93. PubMed doi:10.2165/00023210-200519001-00001
10. Brixner DI, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother. 2006;40(4):626-632. PubMed doi:10.1345/aph.1G564
11. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. PubMed doi:10.2337/diacare.27.2.596
12. DuMouchel W, Fram D, Yang X, et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann Clin Psychiatry. 2008;20(1):21-31. PubMed doi:10.1080/10401230701844612
13. Baker RA, Pikalov A, Tran QV, et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event Database: a Systematic Bayesian Signal Detection Analysis. Psychopharmacol Bull. 2009;42(1):11-31. PubMed
14. Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent: results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009;18(9):791-799. PubMed doi:10.1002/pds.1781
15. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4)266-271. PubMed doi:10.1192/bjp.bp.109.076935
16. Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry. 2007;68(3):406-409. PubMed doi:10.4088/JCP.v68n0308
17. Schorr SG, Slooff CJ, Postema R, et al. A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Acta Psychiatr Scand. 2008;118(3):246-250. PubMed doi:10.1111/j.1600-0447.2008.01232.x
18. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140-1144. PubMed doi:10.1176/appi.ps.57.8.1140
19. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112-117. PubMed doi:10.1176/appi.ajp.160.1.112
20. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67(suppl 9):25-30 PubMed doi:10.4088/JCP.1106e16
21. Friedman JI, Wallenstein S, Moshier E, et al. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry. 2010;167(10):1232-1239. PubMed doi:10.1176/appi.ajp.2010.09091328
22. Keck PE Jr, Marcus R, Tourkodimitris S, et al; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651-1658. PubMed doi:10.1176/appi.ajp.160.9.1651
23. Sachs G, Sanchez R, Marcus R, et al; Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4):536-546. PubMed doi:10.1177/0269881106059693
24. Keck PE, Orsulak PJ, Cutler AJ, et al; 138-135 Study Group. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo-and lithium-controlled study. J Affect Disord. 2009;112(1-3):36-49. PubMed doi:10.1016/j.jad.2008.05.014
25. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo-and haloperidol-controlled study. Br J Psychiatry. 2009;194(1):40-48. PubMed doi:10.1192/bjp.bp.108.049965
26. Vieta E, Bourin M, Sanchez R, et al; Aripoprazole Study Group. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235-242. PubMed doi:10.1192/bjp.187.3.235
27. Keck PE Jr, Calabrese JR, McQuade RD, et al; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626-637. PubMed doi:10.4088/JCP.v67n0414
28. Keck PE Jr, Calabrese JR, McIntyre RS, et al; Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480-1491. PubMed doi:10.4088/JCP.v68n1003
29. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763-771. PubMed doi:10.4088/JCP.v63n0903
30. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325-337. PubMed doi:10.1017/S1461145703003651
31. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123-136. PubMed doi:10.1016/S0920-9964(03)00050-1
32. Pigott TA, Carson WH, Saha AR, et al; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056. PubMed doi:10.4088/JCP.v64n0910
33. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163(10):1821-1825. PubMed doi:10.1176/appi.ajp.163.10.1821
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
35. El-Mallakh R, Marcus RN, Baudelet C, et al. A 52-week, double-blind safety and efficacy evaluation of aripiprazole monotherapy versus lithium in bipolar I disorder (CN138-135LT). Bipolar Disord. 2009;11(suppl 1):63.
36. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65(6):510-517. PubMed doi:10.1016/j.biopsych.2008.07.033
37. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189(2):259-266. PubMed doi:10.1007/s00213-006-0564-3
38. Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord. 2006;8(2):175-181. PubMed doi:10.1111/j.1399-5618.2006.00308.x
39. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163(7):1199-1201. PubMed doi:10.1176/appi.ajp.163.7.1199
40. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? a review for the mental health professional. J Clin Psychiatry. 2004;65(5):634-651. PubMed doi:10.4088/JCP.v65n0507
41. Fagiolini A, Frank E, Turkin S, et al. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry. 2008;69(4):678-679. PubMed doi:10.4088/JCP.v69n0423c
42. Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4-18. PubMed doi:10.1111/j.1600-0447.2008.01204.x
43. Jin H, Meyer J, Mudaliar S, et al. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. J Clin Psychiatry. 2010;71(10):1273-1278. PubMed doi:10.4088/JCP.09m05414yel